New Delhi [India], January 27 (ANI): The Drugs Controller General of India (DCGI) on Thursday granted conditional regular market approval for COVID-19 vaccines Covaxin and Covishield for restricted use in emergency situations in the adult population.
New Delhi [India], January 26 (ANI): The regular market approval from Drugs Controller General of India (DCGI) to COVID-19 vaccine Covishield and Covaxin is expected soon, but only after price fixation which is still underway, official sources told ANI on Wednesday.
New Delhi [India], January 14 (ANI): The Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) will continue thorough review of data submitted by the Serum Institute of India (SII) and Bharat Biotech for granting full market approval to Covaxin and Covishield, sources
New Delhi [India], January 14 (ANI): Drugs Controller General of India (DCGI)'s Subject Expert Committee will review applications of Bharat Biotech and Serum Institute of India (SII) for full market approval to Covaxin and Covishield respectively on Friday, sources said.
Gaithersburg/Pune (Maryland/Maharashtra)[US/India], December 29 (ANI): Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India (SII), the world's largest vaccin
Houston [US], December 29 (ANI): Texas Children's Hospital and Baylor College of Medicine announced on Tuesday (local time) that Corbevax, a protein sub-unit COVID-19 vaccine, whose technology was created and engineered at its Center for Vaccine Development (CVD), has received Emergency Use
Hyderabad (Telangana) [India], December 28 (ANI): Drugs Controller General of India (DCGI) on Tuesday approved Dr Reddy's laboratories for the emergency-use authorisation) to manufacture and market the oral anti-viral drug Molnupiravir capsules 200mg for the treatment of adult patients with
New Delhi [India], December 25 (ANI): Covaxin has a proven record for safety and efficacy from all the variants of COVID-19, said Bharat Biotech after its vaccine received emergency usage approval from the Drugs Controller General of India (DCGI) for kids aged between 12-18 years.
New Delhi [India], December 25 (ANI): Bharat Biotech's COVID-19 vaccine Covaxin has received approval from the Drugs Controller General of India (DCGI) for emergency use for kids aged between 12-18 years, official sources said.
New Delhi [India], December 20 (ANI): As India is witnessing a surge in cases of "highly transmissible" Omicron variant, Hyderabad-based Bharat Biotech has submitted the phase 3 clinical trial application to the Drugs Controller General of India (DCGI) to get approval for the booster dose
New Delhi [India], November 8 (ANI): The data for Bharat Biotech's Covaxin for Children, COVID-19 vaccine, is under evaluation and the process will take some more time for final approval from the Drugs Controller General of India (DCGI), sources said.
New Delhi [India], October 23(ANI): Chairman and Managing Director of Bharat Biotech, Dr. Krishna Ella on Saturday said that they are waiting for approval from the Drugs Controller General of India (DCGI) for the COVID-19 vaccine for children.